Fig 1: Assessing the effect of M42 recombinant proteins on intracellular Ca2+ signaling in human induced pluripotent stem cell‐derived macrophages. (A) Summary graph showing the fold change in total Ca2+ levels following the addition of recombinant M42 proteins. (B–G) Intracellular Ca2+ levels following treatment with TMEFF2 ectodomain (B), MDK (C), SDC4 ectodomain (D), SFRP1 (E), SPON1 (F), and PTN (G). Left panels represent intracellular Ca2+ levels defined as area under the curve (AUC). Right panels show representative traces from one biological repeat (n = 3 technical replicates). Intracellular Ca2+ levels are measured as relative fluorescent units. Histamine (6 µM) was used as a positive control. N = 3 to 6 independent biological experiments (two independent macrophage factory set‐ups; four technical replicates/biological repeat). Error bars correspond to mean ± SD. Repeated measures one‐way ANOVA followed by Dunnett's multiple comparisons test. *p < 0.05, **p < 0.01.
Fig 2: Assessing the effect of M42 protein treatment on viability of hiPSC derived macrophages. Human iPSC macrophages were treated with HTRA1 (A), DAG1 ectodomain (B), TMEFF2 ectodomain (C), MDK (D), GPC5 (E), SDC4 ectodomain (F), SFRP1 (G), SPON1 (H), and PTN (I) at 3 µg/mL, 1 µg/mL, and 100 ng/mL for 24 h. Viability was assessed and expressed as relative luminescence units (RLU). N = 2 or 3 independent biological experiments (one independent macrophage factory set‐up; three technical replicates/biological repeat). Error bars correspond to mean ± standard deviation (SD). Repeated measures one‐way ANOVA followed by Dunnett's multiple comparisons test.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human F-Spondin/SPON1 Protein, CF